AO-176 is an anti-CD47 monoclonal antibody currently being developed for patients with multiple myeloma and select solid tumors. Arch Oncology is evaluating this therapy both as a monotherapy and in combination with standard therapies.

SparkCures ID 391
Developed By Arch Oncology
Generic Name AO-176
Treatment Classifications
Treatment Targets

Clinical Trials


SparkCures Verified

SparkCures is working closely with Arch Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners